Revance Therapeutics Q2 EPS $(0.80) Misses $(0.77) Estimate, Sales $58.13M Miss $59.35M Estimate
Portfolio Pulse from saritha@benzinga.com
Revance Therapeutics reported Q2 losses of $(0.80) per share, missing the analyst consensus estimate of $(0.77) by 3.9%. The company also reported quarterly sales of $58.13 million, missing the estimate of $59.35 million by 2.05%. However, this is a 104.93% increase over sales of $28.37 million the same period last year.
August 08, 2023 | 8:37 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Revance Therapeutics missed Q2 earnings and sales estimates. However, sales increased by 104.93% compared to the same period last year.
Revance Therapeutics missed both earnings and sales estimates for Q2, which could negatively impact the stock price in the short term. However, the significant YoY sales increase might mitigate some of the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100